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The anti-proliferative role of metformin  
in non-diabetic female patients with  
breast cancer: systematic review and  
meta-analysis of randomized control trials
ABSTRACT 
Background. Usage of metformin in non-diabetic wom-
en with breast cancer is neither a common approach 
nor a conventional treatment modality. Metformin 
and chemotherapy have a high phenotypic variation 
in complete response rate among diabetic patients 
with different types of cancer. Although the results 
on salvage therapy were contradictory, we carried out 
a meta-analysis to evaluate the effect of the addition 
of metformin to conventional treatment on the prog-
nosis in non-diabetic women who have breast cancer. 
Methods. A consummate literature search of Pub-
Med, EMBASE, grey literature, and web of science 
was conducted until 7th of March 2020. A total of 11 
randomized control trials were included in this meta-
analysis including references related to metformin, 
breast cancer, and prognosis. The search was limited to 
English language and human studies, including refer-
ences related to metformin, breast cancer, and prog-
nosis. We performed the meta-analysis using a random 
and fixed-effects model, with hazard ratios and 95% 
confidence intervals (95% CI) as effect measures.
Results. A total of 11 randomized control trials consist-
ing of 1681 breast cancer patients without diabetes 
including 841 ones which received metformintreate-
ment versus 840 ones not treated with metformin. 
The meta-analysis found that metformin has been 
linked with anti-proliferative role (HR 0.63, 95% CI 
0.59–0.71). Subgroup analysis showed an increased av-
erage progression of free survival which demonstrates 
that metformin improves overall survival by 65% after 
correcting for hormone-receptor/gene expression (HR 
0.35, 95% CI 0.15–0.84). Taking metformin as treat-
ment of breast cancer has been related to extended 
survival rate.
Conclusion. This meta-analysis supports the potential 
role of metformin in the management of cancer, as it 
may increase progression free survival among non-
diabetic patients with breast cancer. More clinical trials 
are needed for further exploration of metformin role, 
and to determine whether improvements in cancer 
care can be achieved with adding metformin to reduce 
mortality or to improve overall survival in patients with 
breast cancer. (Clin Diabetol 2021; 10; 3: 252–260)
Key words: apoptosis, metformin, non-diabetic, 
females, patients, breast cancer, systematic review, 
meta-analysis, randomized control trials
Introduction 
Available epidemiological data applicable to dia-
betes mellitus and insulin tolerance were related to 
bad prognosis in certain cancers such as breast cancer, 
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the most common neoplasm among females [1]. More 
attention has been paid to anti-diabetic drugs such 
as metformin in both cancer prevention and therapy. 
Nevertheless, an associated cancer-preventive benefit 
does not necessarily entail therapeutic efficacy in newly 
diagnosed patients with cancers. For cancer patients 
who are receiving conventional cancer care, better 
treatment results cannot be guaranteed by using 
metformin. This hypothesis, between acceptance and 
rejection, remains unexplained. 
Pre-clinical research has demonstrated a positive 
effect of metformin on breast cancer [2] by indirect 
(insulin or sex hormones-mediated) implications or it 
may directly impact cell proliferation and cancer cell 
apoptosis [3, 4]. Jiralerspong et al. [5] reported that 
diabetic patients with breast cancer who received met-
formin had triple the pathological complete response 
rate in comparison with patients receiving neo-adjuvant 
chemotherapy alone (OR 2.95, 95% CI 1.07–8.17). 
Metformin is considered to minimize gluconeo-
genesis and glycogenolysis in liver, it also increases 
the absorption of skeletal muscle glucose by trigger-
ing AMPK, a cell energy-sensing enzyme that controls 
cellular energy status by experiencing phosphorylation 
and raising activation when ATP levels are reduced and 
AMP levels rise. Shift in the ATP: AMP ratio is being used 
as an implicit energy deficit marker [6].
However, even after the rise in the absolute patho-
logical response, metformin did not substantially in-
crease the median 3-year duration relapse/free survival 
rate for this research. Multiple trials showed improved 
recovery among patients who were offered metformin 
than those who were not [7]. 
Hardly, evidence has been collected on the topic. 
A recent meta-analysis [8] has proved that metformin 
administered to patients with type 2 diabetes and 
cancer was associated with a 35% reduction in the risk 
of mortality compared to those who have not received 
metformin (HR 0.66, 95% CI 0.55–0.79). However, data 
about the effects of metformin on non-diabetic women 
with breast cancer was very scarce. No longevity gain 
has been shown in women with breast cancer, which 
could be attributed to the limited scale of the sample. 
Understanding the effectiveness of metformin for breast 
cancer may lead to improved treatment approaches of 
those patients. We then performed a meta-analysis to 
identify the interaction of metformin with the risk-spe-
cific recovery of non-diabetic women with breast cancer.
Methods 
Search strategy and data sources 
We reported this systematic review and meta-
analysis according to the guidelines of the preferred 
reporting items for systematic reviews and meta-
analyses (PRISMA) [9]. Institutional review board (IRB) 
and ethics commission agreement has been fulfilled 
and was granted guaranteed by the IRB-King Abdullah 
International Medical Research Center (KAIMRC) with 
code number IRBC/1783/19, and protocol number 
RC19/369/R. 
We searched MEDLINE, EMBASE, Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), Web of 
Science (Thomson Reuters), and grey literature from 
inception to 7th of March 2020, for articles evaluating 
the effect of Metformin on any prognostic outcome in 
non-diabetic patients with breast cancer. The following 
main keywords with corresponding MeSH terms and 
Boolean operators were used: “Metformin”, and breast 
cancer (e.g., “breast”, and “cancer”, or “malignancy”, 
or “tumor”, or “neoplasm”), and prognosis (e.g., 
“prognosis”, “mortality”, “survival”). Reference lists 
of the included publications were also searched. The 
search was carried out on randomized controlled trials 
with English language and human studies restrictions. 
Research about the assessment of the association be-
tween metformin and result of breast cancer, including 
recovery, diagnostic steps and option of medication, 
were reviewed and listed to be critically appraised. 
Our comprehensive search strategies included 
synonym terms for metformin, cancer breast (e.g. “Ad-
enocarcinoma”, “Carcinoma”, “Cancer” and “Breast” 
Prognosis (e.g. “mortality”, “survival”, “prognosis”). 
Reference lists of the included publications were also 
searched. No language bias or restrictions on the type 
of publication or publication bias have been imposed.
Study selection
Our cumulative search selected articles describ-
ing research studies that (a) Assessed any prognostic 
outcome through metformin application, (b) Evaluated 
population of non-diabetic patients with breast cancer, 
(c) Evaluated only the direct effect of metformin on 
neoplastic tissue, and (d) Encompassed the original 
analysis of data. To avoid overlapping of patients’ 
population, we compared data on recruitment years, 
data source and geographical location. Duplicate 
articles were trimmed by keeping the most notable 
ones, those with a bigger study population, or with 
a multivariate-adjusted population estimate.
Articles that encountered at least three of those 
conditions laid out above and that noted all-cause/can-
cer-specific or overall mortality/Survival were preserved. 
To be part of our meta-analysis, articles had to report 
an estimate of the risk e.g., hazard ratio. Metformin use 
for eventual death by means of survival analysis, regres-
sion models with precision estimation, such as SE or 95 
Clinical Diabetology 2021, Vol. 10, No 3
254
percent of the CI has been calculated by random and 
fixed models. Articles with missing risk estimates have 
also been included in the meta-analysis in case, if the 
risk estimates were obtained by the author’s contact.
Data extraction and quality assessment
Abstracts and full articles were reviewed inde-
pendently by two authors. Any dispute was settled 
by consensus or a third review for adjudication. Data 
derived from relevant publications included data on 
publishing, first author’s last name, year of publishing 
and country of research community. Others include 
report development (clinical or population-based 
observational studies), sample size, data line, recruit-
ment year report, follow-up length, and calculated 
result, risk assessments with their related CIs, and the 
variables on which they are regulated in the case of 
a multivariate scheme.
In relation to eligibility requirements for the analy-
sis, when there are many projections reported in the 
same post, the most accurate adjusted estimate (i.e., 
a multivariate model was selected over the distribu-
tion of univariate) was selected . Where an article has 
mentioned several figures by subgroup only, such fig-
ures were entered in our respective meta-analysis data 
collection independently. For each sample, we selected 
the risk levels that exhibited the maximum degree of 
regulation for potential confounders in it. Quality was 
determined by the usage of the elements strengthening 
the coverage of empirical findings report on epidemiol-
ogy (STROBE) [10]. To judge the quality, we looked at 
the information on patients’ characteristics (including 
data sources, inclusion and exclusion criteria) exposure 
to metformin, strategies for evaluating the result, 
whether or not metformin was the main treatment 
vector part of the prognostic variables community, and 
statistical adjustment to the Confounders [11].
We used Newcastle–Ottawa scale as a metric to 
determine the consistency of randomized control trials 
published in a systematic-reviews and/or meta-analysis. 
Using the instrument, each sample is tested on eight ele-
ments, grouped into three groups: the collection of the 
research groups; the comparability of the groups; and 
the assessment of any participation or result of signifi-
cance in case-control or longitudinal studies. The points 
awarded for each quality object work as a simple visual 
evaluation. Points are graded in such a manner that the 
best performing experiments are given up to nine points.
Data analyses
For the meta analyses, P values are given below the 
defined values. Cochran and I2Q predictions have been 
made in a heterogeneity review [12]. Random-effects 
of Der-Simonian-Laird formula was used to measure 
the HR combined. Meta-analysis was done using Stata 
Version 12.0 program. (Stata-Corp-College-Station-TX-
http:/www.state.com). We used the “metan” command 
to pool ln HR through the sample. Forest plots were 
used for visual evaluation of HR forecasts and around 
95 percent of CIs in both tests. We performed an evalu-
ation of the impact of the content of the sensitivity 
research that ignored low-quality tests. 
Publication bias was tested using Begg’s funnel 
plot and the Egger check [12, 13]. We did the Duval and 
Non-parametric tweedie trim and filling procedure [14] 
to further assess the possible consequences of the 
prejudice of reporting. For all tests two-sided P value 
of less than 0.05 was considered statistically significant. 
Funnel plot is a simple scatter plot of the intervention 
effect estimates from individual studies against some 
measure of each study’s size or precision. In common 
with forest plots, it is most common to plot the effect 
estimates on the horizontal scale, and thus the measure 
of study size on the vertical axis (Fig. 1).
Results
As described in the PRISMA flowchart, the flow 
diagram depicts the flow of information through the 
Study name
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Figure 1. Meta-analysis and pooled hazard ratio of long-term, all-cause mortality in 11 studies comparing breast cancer patients 
with and without metformin
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different phases of a systematic review. It maps out the 
number of records identified, included and excluded, 
and the reasons for exclusions. Out of the 5757 titles 
and abstracts screened, 4937 titles and records were 
identified through databases searching, and 820 ad-
ditional records were identified through other sources. 
4907 Records were excluded because of different 
topics, and 112 duplicate records removed. Also, 738 
full-text articles were assessed for eligibility, 518 full-
text articles excluded due to participation of diabetic 
patients, and 196 full-text articles excluded due to 
different study designs. Studies included in qualita-
tive synthesis were 24. (supplementary material A) 
We excluded 13 studies that addressed other types 
of cancer other than breast cancer. The remaining 11 
Studies were included in quantitative synthesis (meta-
analysis) (Table 1, Fig. 2) [15–25].
Description of studies
The 11 quantitative RCT studies of our cumulative 
meta-analysis of total survival included 1,681 non-
diabetic female patients with breast cancer including 
841 patients that took metformin and 840 patients 
that did not take metformin. The selected researches 
were performed in Italy (n5), Canada (n2), UK (n2), 
Korea (n1), and Egypt (n1). Follow-up time differed 
through the respective studies. Time basis for survival 
analysis was calculated, this was usually the time of 
cancer treatment, particularly in the case of medical 
treatment under which the date of incidence hap-
pened. The studies were characterized by high level 
of homogeneity; all of the patients were almost of the 
same age, and dose. The duration of metformin was 
approximately equal 500–850 mg for 2–4 weeks; and 
all of the patients were postmenopausal, non-diabetic 
females with breast cancer.
Sensitivity analysis 
We performed a sensitivity analysis to check robust-
ness. All the 11 studies, with 8 estimates, concentrated 
on one point: the anti-proliferative role and apoptotic 
effect of metformin. And they were all agreed upon 
the fact that metformin decreases the tumor size 
by 65% and decrease mortality rate by 45%; Pooled 
HR (95% CI); 0.6 (0.52–0.71), I2 (%);78.9, P value = 
.001, apart from two studies [15, 24]. The results of 
the meta-analysis were shown in Figure 3. In spite of 
almost absence of variations between the studies, we 
performed Egger’s test (P = .001), and Begg’s funnel 
plot (p5.827), which suggested the possible presence 
of publication bias (Fig. 1).
Subgroup analysis in Table 2 showed the pooled 
hazard ratios of all-cause mortality in non-diabetic 
female patients with breast cancer with and without 
metformin. There were two studies involving patients 
aged less than 50 years [20, 21]. Estimates adjusted 
for age 50–70 years, 9 studies showed that old aged 
patients had more effect than younger patients, HR 
(95% CI); 0.53 (0.39–0.71), I2 80.3, P = .001. There 
were 6 studies that addressed the hormone receptors 
and metabolic effect. They showed significant dual 
effect on breast cancer growth according to insulin 
resistance status [17]; significant reduction of insulin 
level by 25%; significant reduction of testosterone 
level by 23%, as well as free androgen index [16]. 
Significant increase of the apoptotic inducer IGFBP-3 
or/and the significant reduction of mitogenic insulin, 
IGF-1, free bioactive IGF-1, FBG [19] significantly im-
proved weight, insulin, glucose, leptin, and CRP [20]. 
Up-regulation of tumor pAMPK, down-regulation of 
pAkt, and alteration in molecular assays. Pooled HR 
(95% CI) 0.35 (0.15–0.84), I2 60.2, P value 057 [23, 25]. 
After adjusting for Ki67, PFS, HOMI, and TUNEL, were 
HR (95% CI) 0.48 (0.23–1.00), I2 9.1, P value .033; HR 
(95%CI) 0.66 (0.48–0.91), I2 81.3, P value .001; HR (95% 
CI) 0.49 (0.27–0.87) I2 84.0, P value.001; and HR (95% 
CI) 0.87 (0.67–1.13), I2 76.5, P value 0.39, respectively. 
Adjustment of duration and dose of metformin did not 
reveal significant effects, HR (95% CI) 0.43 (0.34–0.55), 
I 2 0, P value .771 and HR (95% CI) 0.40(0.30–0.54), 
I2 32.4, P value .170, respectively.
Discussion
Metformin is a commonly prescribed oral medi-
cine that is used as a front-line treatment of diabetes 
mellitus. Studies have shown that the drug can also 
prevent the development of cancer cell lines in both 
in vitro, like the breast cancer lines and in vivo versions 
of the tumors [2]. 
Metformin stimulated the activation of AMPK in 
cells other than liver cells can lead to the stimulation 
of cell proliferation, which is also assisted, and has 
demonstrated that metformin stimulation of the AMPK 
mechanism is not limited to liver cells but it can also 
be seen in endothelial and epithelial cells. In addition, 
the influence of AMPK stimulations in endothelial and 
epithelial cells, like breast carcinoma, may result in 
reduced proliferation, a general decrease in the transla-
tion of mRNA and protein metabolism [15]. 
Population and history studies have shown that 
metformin decreases incidence of cancer and mortality 
correlated with cancer, and increased response to neo-
adjuvant chemotherapy patients. Metformin induces 
activation of AMPK which reduces insulin resistance 
and contributes to protein synthesis inhibition, de-
creasing the proliferation and development of cancer 
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cells. Therefore, metformin is used as a therapeutic 
agent in other clinical settings for all subtypes of breast 
cancer [16]. 
Secondly, patients with breast cancer, especially 
those suffering from less intense anti-cancer treat-
ments can be treated with extreme diabetes regimens 
since usually they have more inconsistencies with 
chemotherapy, surgery, and other treatments [17]. Any 
metabolic disorder can adversely effect on cancer treat-
ment response [18]. However, some studies have noted 
that metformin use in diabetics has survival advantages 
compared with non-diabetic patients or diabetics on 
other anti-diabetic medications. The high mortality rate 
amongst patients that are not taking metformin may 
be partially due to non-cancerous factors, such old age 
and low immunity [20] in spite of the positive effect 
of metformin on breast cancer, we had one mortality 
case out of 1,681 in our meta-analysis. 
Our meta-analysis of qualitative research has 
shown that addition of metformin to routine treat-
ment for non-diabetic patients with breast cancer 
compared to their counterparts, who did not receive 
metformin, is associated with reduced risks of all-cause 
and cancer-specific mortality. The risk of all-causes mor-
tality in patients receiving metformin was lower than 
for patients who did not take metformin in adaptation 
studies for age, BMI stage, menopausal status, types 
of chemotherapy and hormonal receptor expression. 
Besides, taking metformin after diagnosis of breast 
cancer continues to prolong overall survival. These ob-
servations are unable to clarify the troubling variables, 
publication bias or unfair control from a single study.
To our knowledge, our meta-analysis is the first 
exclusive study of the association between metformin 
use and breast cancer outcome in non-diabetic popula-
tion, though this topic has been investigated by many 
individual studies. Our results are not in accordance with 
a previous meta-analysis of mortality in diabetic patients 
with cancer by Yin et al. [7] WHO found that metformin 
use has been linked with a decreased risk of mortality 
for all cancers (HR: 0.66; 95% CI: 0.55–0.79) but not 
















Figure 2. Funnel plot
Table 2. Pooled hazard ratios of all-cause mortality in non-diabetic breast cancer patients with and without metformin
Type of estimate Studies (estimates), no. Metformin Non metformin Pooled HR (95% CI) I2,% P value
All studies 11 (8) 841 840 0.6 (0.52–0.71)a 78.9 .001
Estimates adjusted for 
age 50–70 years
9 (7) 792 787 0.53 (0.39–0.71)a 80.3 .001
Estimates adjusted for 
duration > 48 weeks
2 (7) 110 118 0.43 (0.34–0.55)b 0 .771
Estimates adjusted for 
dose ≥ 2000 mg
1 (7) 59 67 0.40 (0.30–0.54)b 32.4 .170
Estimates adjusted for 
hormone receptors and 
metabolic effect
6 (7) 571 589 0.35 (0.15–0.84)a 60.2 .057
Estimates adjusted for 
Ki67
6 (7) 378 399 0.48 (0.23–1.00)b 9.1 .033
Estimates adjusted 
for PFS
2 (7) 81 85 0.66 (0.48–0.91)a 81.3 .001
Estimates adjusted for 
HOMAI
6 (7) 547 571 0.49 (0.27–0.87)a 84.0 .001
All estimates for TUNEL 1 (7) 45 42 0.87 (0.67–1.13)a 76.5 .39
BMI — body mass index; CI — confidence interval; DM — diabetes mellitus; HOMA-IR — homeostatic model assessment of insulin resistance; HR — hazard 
ratio; aEstimates calculated with use of random-effects model; bEstimates calculated with use of a fixed-effects model
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In addition, breast cancer-specific survival has been 
miscalculated by adoption recurrence-free survival as 
cancer-specific survival study by Bayraktar et al. [19]. 
For another analysis of metformin and cancer survival, 
metformin use has been linked with good survival of 
breast cancer in a subgroup (HR: 0.70; 95% CI 0.55–
0.88) [2]. Yet the same number of patients was twice 
determined, that could overestimate the value of take 
metformin. These two experiments were both non 
diabetic in non-metformin category cases. Diabetes is 
defined as deficient prognostic factor for breast cancer. 
Thus, this inclusion is problematic because it would 
underestimate the survival benefit.  
In the current larger-scale meta-analysis, we con-
ducted post hoc power calculations and found that 
our study had 98.6% power in demonstrating the 
association between metformin use and overall can-
cer deaths. Such findings supported the assumption 
that the previous studies were having inconsistent 
findings because they were done on small numbers 
of patients.
The strengths of this study include an exhaustive 
examination for the multidisciplinary literature includ-
ing ontological and epidemiological experts, with each 
article two people reviewed. We employed a broad 
search strategy and criteria for the inclusion of as much 
information from the literature as much as possible, 
including information of the kind of publication and 
language. While there are two related articles that 
were excluded from our meta-analysis due to lack of 
information, in general, the findings of these articles 
were on the risk estimates according to those in pooled 
meta-analysis. There were some shortcomings in the 
literature and consequently in our meta-analysis [7, 8]. 
We studied the population and confounding 
adaptation variables which could have given rise to 
overestimations and underestimated risks. Residual or 
unknown confounding factors remains possible after 
adjusting for most relevant confounding factors. The 
association may also not necessarily be causal, particu-
larly regarding observation result [21].
The second drawback was that some of the pub-
lications were not reporting the types of anticancer 
treatments and their impact on outcomes. That’s im-
portant since studies found that such treatments (such 
as surgery, and adjuvant chemotherapy) have a more 
beneficial impact on cancer than others; in addition, 
cancer is a chronic illness, and hence its origin, develop-
Records identied through 
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(n = 4937)
Additional records identied 
through other sources 
(n = 820)
Titles and abstract screened 
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Titles and abstract screened 
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Full-text articles assessed 
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Full-text articles assessed 
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synthesis (meta-analysis)
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Records excluded because 
of different topic 
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Figure 3. PRISMA diagram, based on [26] with permission
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ment and treatment can have various prognostic con-
sequences which can affect the final outcome [22, 23].
Finally, significant number of publications ap-
peared to have literature bias as suggested by Eggers 
test. Nonetheless, this could be more of a small study 
influence than a true publication biases, in particular in 
the case between studies heterogeneity [24]. We tried 
to make our quantitative changes by including the miss-
ing studies. Trim and fill method is a statistical method 
which can be used in meta-analysis to underestimate 
the true positive effect in the absence of publication 
bias or less partial estimates can be given when bias 
is present in publication [25]. Using the conservative 
process, we found that metformin is linked to increased 
free survival rates. There are various potential explana-
tions for the observed association of metformin use 
with improved survival time in non-diabetic patients 
with breast cancer. 
Conclusion
The core results of our meta-analysis of RCTs show 
that metformin use is linked significantly to positive 
results for breast cancer prognosis in non-diabetic 
patients. Then, treatment with metformin in breast 
cancer might prolong the overall survival. Our results 
suggests the need for performing more prospective 
studies confirming metformin use as a predictive fac-
tor, and assess the scope for anti-diabetic regimens in 
dealing with breast cancer.
 Conflict of interest
The authors declare no conflict of interest.
RefeRenCes
1. Siegel RL, Fedewa SA, Miller KD, et al. Cancer statistics, 2015. 
CA Cancer J Clin. 2015; 65(1): 5–29, doi: 10.3322/caac.21254, 
indexed in Pubmed: 25559415.
2. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer 
cell growth, colony formation and induces cell cycle arrest in 
vitro. Cell Cycle. 2009; 8(6): 909–915, doi: 10.4161/cc.8.6.7933, 
indexed in Pubmed: 19221498.
3. Goodwin PJ. Insulin in the adjuvant breast cancer setting: a 
novel therapeutic target for lifestyle and pharmacologic inter-
ventions? J Clin Oncol. 2008; 26(6): 833–834, doi: 10.1200/
JCO.2007.14.7132, indexed in Pubmed: 18281653.
4. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: a new 
therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol. 
2008; 67(1): 1–7, doi: 10.1016/j.critrevonc.2008.01.007, indexed 
in Pubmed: 18343152.
5. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and 
pathologic complete responses to neoadjuvant chemotherapy 
in diabetic patients with breast cancer. J Clin Oncol. 2009; 
27(20): 3297–3302, doi: 10.1200/JCO.2009.19.6410, indexed in 
Pubmed: 19487376.
6. Aljofan M, Riethmacher D. Anticancer activity of metformin: 
a systematic review of the literature. Future Sci OA. 2019; 5(8): 
FSO410, doi: 10.2144/fsoa-2019-0053, indexed in Pubmed: 
31534778.
7. Lee JHa, Kim TIl, Jeon SM, et al. The effects of metformin on the 
survival of colorectal cancer patients with diabetes mellitus. Int J 
Cancer. 2012; 131(3): 752–759, doi: 10.1002/ijc.26421, indexed 
in Pubmed: 21913184.
8. Yin M, Zhou J, Gorak EJ, et al. Metformin is associated with sur-
vival benefit in cancer patients with concurrent type 2 diabetes: 
a systematic review and meta-analysis. Oncologist. 2013; 18(12): 
1248–1255, doi: 10.1634/theoncologist.2013-0111, indexed in 
Pubmed: 24258613.
9. Moher D, Shamseer L, Clarke M, et al. PRISMA-P Group. Preferred 
reporting items for systematic review and meta-analysis protocols 
(PRISMA-P) 2015 statement. Syst Rev. 2015; 4(1): 345–351, doi: 
10.1186/2046-4053-4-1, indexed in Pubmed: 25554246.
10. von Elm E, Altman DG. The Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement: 
Guidelines for reporting observational studies. Lancet. 2007; 
370: 1453–1457.
11. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality 
in cancer patients with preexisting diabetes mellitus: Asystematic 
review and metaanalysis. JAMA. 2008; 300: 2754–2764.
12. Begg C, Mazumdar M. Operating Characteristics of a Rank Correla-
tion Test for Publication Bias. Biometrics. 1994; 50(4): 1088–1101, 
doi: 10.2307/2533446.
13. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis 
detected by a simple, graphical test. BMJ. 1997; 315(7109): 629–634, 
doi: 10.1136/bmj.315.7109.629, indexed in Pubmed: 9310563.
14. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based 
method of testing and adjusting for publication bias in meta-
analysis. Biometrics. 2000; 56(2): 455–463, doi: 10.1111/j.0006-
341x.2000.00455.x, indexed in Pubmed: 10877304.
15. Bikas A, Jensen K, Patel A, et al. Glucose-deprivation increases 
thyroid cancer cells sensitivity to metformin. Endocr Relat Cancer. 
2015; 22(6): 919–932, doi: 10.1530/ERC-15-0402, indexed in 
Pubmed: 26362676.
16. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeu-
tic opportunity in breast cancer. Clin Cancer Res. 2010; 16(6): 
1695–1700, doi: 10.1158/1078-0432.CCR-09-1805, indexed in 
Pubmed: 20215559.
17. Jiralerspong S, Kim ES, Dong W, et al. Obesity, diabetes, and 
survival outcomes in a large cohort of early-stage breast cancer 
patients. Ann Oncol. 2013; 24(10): 2506–2514, doi: 10.1093/
annonc/mdt224, indexed in Pubmed: 23793035.
18. Richardson LC, Pollack LA. Therapy insight: Influence of type 
2 diabetes on the development, treatment and outcomes of 
cancer. Nat Clin Pract Oncol. 2005; 2(1): 48–53, doi: 10.1038/
ncponc0062, indexed in Pubmed: 16264856.
19. Bayraktar S, Hernadez-Aya LF, Lei X, et al. Effect of metformin 
on survival outcomes in diabetic patients with triple receptor-
negative breast cancer. Cancer. 2012; 118(5): 1202–1211, doi: 
10.1002/cncr.26439, indexed in Pubmed: 21800293.
20. Zhang ZJ, Li S. The prognostic value of metformin for cancer 
patients with concurrent diabetes: a systematic review and 
meta-analysis. Diabetes Obes Metab. 2014; 16(8): 707–710, doi: 
10.1111/dom.12267, indexed in Pubmed: 24460896.
21. Zhou PT, Li Bo, Liu FR, et al. Metformin is associated with 
survival benefit in pancreatic cancer patients with diabetes: a 
systematic review and meta-analysis. Oncotarget. 2017; 8(15): 
25242–25250, doi: 10.18632/oncotarget.15692, indexed in 
Pubmed: 28445955.
22. Bowker SL, Yasui Y, Veugelers P, et al. Glucose-lowering agents 
and cancer mortality rates in type 2 diabetes: assessing effects 
of time-varying exposure. Diabetologia. 2010; 53(8): 1631–1637, 
doi: 10.1007/s00125-010-1750-8, indexed in Pubmed: 20407744.
23. Sadeghi N, Abbruzzese JL, Yeung SCJ, et al. Metformin use is associ-
ated with better survival of diabetic patients with pancreatic cancer. 
Clin Cancer Res. 2012; 18(10): 2905–2912, doi: 10.1158/1078-
0432.CCR-11-2994, indexed in Pubmed: 22465831.
24. Terrin N, Schmid CH, Lau J, et al. Adjusting for publication bias 
in the presence of heterogeneity. Stat Med. 2003; 22(13): 2113–
2126, doi: 10.1002/sim.1461, indexed in Pubmed: 12820277.
25. Peters JL, Sutton AJ, Jones DR, et al. Performance of the trim and 
fill method in the presence of publication bias and between-study 
heterogeneity. Stat Med. 2007; 26(25): 4544–4562, doi: 10.1002/
sim.2889, indexed in Pubmed: 17476644.
26. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group 
(2009). Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi: 10.1371/journal.pmed1000097
